Healthcare

• Immutep shares rose13.73%toAUD 0.058.• The company has a market capitalisation of approximatelyAUD 85.48 million.• The stock remains75.83% lower over the past year, providing important context to the latest rally.• Investors continue monitoring clinical progress, trial outcomes and future milestones across the company's immunotherapy …

• BCAL Diagnostics shares rose12.33%toAUD 0.082.• The company has a market capitalisation of approximatelyAUD 30.23 million.• The stock is24.24% higher over the past year, providing broader context for the latest rally.• Investors continue monitoring commercial expansion, product launches and strategic partnerships across BCAL's diagnostics …

Mayne Pharma Group Limited (ASX: MYX) enters the second half of 2026 as an independent, ASX-listed company weighing how best to rebuild its shareholder-value story after a major takeover fell over. The central question for investors is straightforward: what is Mayne Pharma's next strategic …

Clinuvel Pharmaceuticals Limited (ASX: CUV) has secured a regulatory milestone that extends the global reach of its flagship rare-disease therapy. The Melbourne-based biopharmaceutical company confirmed that Health Canada has approved Scenesse (afamelanotide) for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), …

Leadership transitions at the top of a company's finance function rarely grab headlines the way takeovers or profit warnings do — but for investors, few roles matter more to confidence in the numbers. On Monday 13 July 2026, Regis Healthcare (ASX: REG), one of …

4DMedical Ltd (ASX:4DX) attracted investor attention during afternoon trading on 13 July 2026, with its shares rising 1.01% to AUD 4.00. While the daily move was relatively modest, the company's longer-term performance remains notable, with the stock continuing to trade 1,566.67% higher than its …

The Australian share market's Monday morning weakness on 13 July 2026 had several sources, but healthcare was prominent among them — and ResMed Inc. (ASX: RMD) was one of the sector's heaviest fallers. By around 11.04am AEST, ResMed's ASX-listed securities were trading at $28.60, …